Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs

Stat Med. 2013 Dec 30;32(30):5469-83. doi: 10.1002/sim.5886. Epub 2013 Jun 26.

Abstract

Crossover studies are frequently used in clinical research as they allow within-subject comparisons instead of the between-subject evaluation of parallel group designs. Estimation of interesting parameters from such designs is, however, not trivial. We provide three methods for estimating treatment effects and associated standard errors from an AB/BA crossover trial. Assuming at least asymptotic normality, we can obtain the confidence intervals for single parameters as well as for differences or ratios of treatment effects. The latter is particularly useful in a pharmacokinetic context to establish bioequivalence using area under the concentration versus time curves (AUCs). In this work, we will illustrate how Fieller-type confidence intervals can be constructed for the ratio of AUCs estimated using a noncompartmental approach in a sparse sampling setting from a two-treatment, two-period, two-sequence crossover trial. In particular, we will discuss a flexible batch design, which includes traditional serial sampling and complete data designs as special cases. Via simulation, we show that the proposed intervals have nominal coverage and keep the type I error even for small sample sizes. Moreover, we illustrate the methodology in a real data example.

Keywords: 2 × 2 × 2 crossover; PK parameter; Satterthwaite's approximation; area under the concentration versus time curve; bioequivalence; noncompartmental.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin Receptor Antagonists / pharmacokinetics
  • Area Under Curve*
  • Clinical Trials as Topic / methods*
  • Computer Simulation
  • Confidence Intervals
  • Cross-Over Studies*
  • Data Interpretation, Statistical*
  • Humans
  • Hypertension / drug therapy
  • Male
  • Models, Statistical*
  • Therapeutic Equivalency*
  • Treatment Outcome

Substances

  • Angiotensin Receptor Antagonists